[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628366":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":19,"centralContacts":20,"locations":26,"responsibleParty":40,"collaborators":19,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":53,"minAge":54,"maxAge":19,"enrollmentInfo":55,"targetDuration":19,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":28,"whyStopped":19,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Belarusian State Medical University","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"MA data and blood samples data","Patients with MA lesions and suspicion of acute or chronic vascular diseases of the intestine. Patients with suspicion of AMI or CMI are to be included and blood samples are to be collected. Blood samples is the only intervention.",[12],"Diagnostic Test: Blood samples",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"DIAGNOSTIC_TEST","Blood samples","Blood samples as diagnostic tests are the only intervention in the trial",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Hleb But-Husaim, PhD","CONTACT","+375256139407","dr.buthusaim@gmail.com",[27],{"facility":5,"status":28,"city":29,"state":19,"zip":19,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"RECRUITING","Minsk","Belarus","BY",{"type":33,"coordinates":34},"Point",[35,36],27.56653,53.90019,{"lat":36,"lon":35},[39],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},{"type":41,"investigatorFullName":42,"investigatorTitle":43,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"PRINCIPAL_INVESTIGATOR","Hleb But-Husaim","Associate Professor of the Department of Surgery and Endoscopy BSMU, MD, PhD","100628366","mesenteric-ischemia-markers-study-100628366",false,"NCT07460700","Mesenteric Ischemia Markers Study","Mesenteric Ischemia Markers Study In The Presence Of Mesenteric Arteries Disease","MESMARK","Inclusion Criteria:\n\n* 18 years or older, all sex\n* Initial decision, the presence of angio-visualisation of the MA and suspicion of mesenteric arteries diseases\n* Patient's consent to participate in the study\n* No pregnancy, no history of major operations on MA, the gastrointestinal tract and digestive organs (except appendectomy, endoscopic polypectomy).\n\nExclusion Criteria:\n\n* Consent declined by patient or relatives\n* Failure to meet inclusion criteria",true,"ALL","18 Years",{"count":56,"type":57},120,"ESTIMATED","INTERVENTIONAL",[60],"NA","Vascular bowel disease remains a socially significant and potentially fatal condition (if it develops into AMI), primarily due to delayed diagnosis. Blood biomarkers are theoretically ideal for early risk stratification (like troponins in myocardial infarction). However, the existing evidence base is characterized by low quality and high heterogeneity, which hinders their use in clinical practice. Therefore, there is an urgent and unmet clinical need for high-quality, methodologically rigorous research to validate biomarkers in MI. A current study (MESMARK) is to be undertaken to identify combinations of biomarkers that can reliably identify mesenteric ischemia (MI) and distinguish between non-transmural and transmural clinical relevant ischemia.",[63],"Mesenteric Vascular Disease",[65,66,67],"Mesenteric arteries disease","Mesenteric Ischemia","Blood biomarkers","2026-03-04",{"date":70,"type":71},"2026-03-10","ACTUAL",{"date":73,"type":71},"2025-12-22",{"date":75,"type":57},"2026-12-12",{"name":5,"class":6},1]